Cui Wei, Li Feng, Yuan Qiang, Chen Gang, Chen Cailing, Yu Bo
Department of General Surgery, The Military General Hospital of Beijing PLA, Beijing 100700, China.
Department of Health, The Military General Hospital of Beijing PLA, Beijing 100700, China.
Oncotarget. 2017 Nov 6;8(62):105472-105478. doi: 10.18632/oncotarget.22295. eCollection 2017 Dec 1.
This study aimed to explore the effects of vascular endothelial growth factor A () gene polymorphisms (rs699947 and rs833061) on Bevacizumab (BEV) treatment in colorectal cancer (CRC) patients.
125 CRC cases receiving BEV plus FOLFIRI treatment were recruited in this study. polymorphisms were genotyped using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. Correlation of gene polymorphisms with the response rate and progression free survival (PFS) was evaluated. Multivariate analyses were performed to estimate the effects of polymorphisms on the therapeutic effects of BEV treatment in CRC patients.
Rs699947 variants did not show significant association with BEV treatment. For rs833061 analysis, TT and TC genotype carriers had significantly higher ORR (objective response rate) than CC carriers (=0.048 and =0.021, respectively). Moreover, TT carriers underwent a well DCR (disease control rate) compared to CC carriers (=0.002). PFS time also showed obvious correlation with rs833061 polymorphism (log rank test, =0.002). Multivariate analyses demonstrated that TT and TC genotypes of rs833061 polymorphism were significantly correlated with enhanced therapeutic effects and prolonged PFS in CRC patients.
rs833061 polymorphism is significantly associated with the therapeutic efficiency of bevacizumab in CRC patients.
本研究旨在探讨血管内皮生长因子A（VEGF-A）基因多态性（rs699947和rs833061）对结直肠癌（CRC）患者贝伐单抗（BEV）治疗效果的影响。
本研究招募了125例接受BEV联合FOLFIRI治疗的CRC患者。采用聚合酶链反应-限制性片段长度多态性（PCR-RFLP）方法对VEGF-A基因多态性进行基因分型。评估VEGF-A基因多态性与缓解率和无进展生存期（PFS）的相关性。进行多变量分析以评估VEGF-A基因多态性对CRC患者BEV治疗效果的影响。
Rs699947变异与BEV治疗无显著相关性。对于rs833061分析，TT和TC基因型携带者的客观缓解率（ORR）显著高于CC携带者（分别为P = 0.048和P = 0.021）。此外，与CC携带者相比，TT携带者的疾病控制率（DCR）良好（P = 0.002）。PFS时间也与rs833061多态性显著相关（对数秩检验，P = 0.002）。多变量分析表明，rs833061多态性的TT和TC基因型与CRC患者治疗效果增强和PFS延长显著相关。
rs833061多态性与CRC患者贝伐单抗的治疗效果显著相关。
